

Xin-Ting Sang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8115612/publications.pdf>

Version: 2024-02-01

114
papers

2,516
citations

236925

25
h-index

265206

42
g-index

125
all docs

125
docs citations

125
times ranked

3616
citing authors

#	ARTICLE	IF	CITATIONS
1	A Nomogram to Predict Individual Survival of Patients with Liver-Limited Metastases from Gastroenteropancreatic Neuroendocrine Neoplasms: A US Population-Based Cohort Analysis and Chinese Multicenter Cohort Validation Study. <i>Neuroendocrinology</i> , 2022, 112, 263-275.	2.5	3
2	Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency. <i>Hepatology</i> , 2022, 75, 1058-1059.	7.3	0
3	A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, , 1.	4.2	8
4	A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. <i>Genome Medicine</i> , 2022, 14, 20.	8.2	26
5	Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 785535.	2.8	6
6	Conversion therapy of stage IVb unresectable gallbladder carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 335-337.	1.5	2
7	Ultrasound-Guided Continuous Thoracic Paravertebral Block Improves Patient's Quality of Recovery After Open Hepatectomy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Chinese Medical Sciences Journal</i> , 2022, 37, 15.	0.4	0
8	Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16155-e16155.	1.6	2
9	Genomic characterization and translational immunotherapy of microsatellite instability-high (MSI-H) in cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4101-4101.	1.6	0
10	Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	46
11	Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. <i>International Immunopharmacology</i> , 2021, 90, 107164.	3.8	15
12	Association of a novel PKHD1 mutation in a family with autosomal dominant polycystic liver disease. <i>Annals of Translational Medicine</i> , 2021, 9, 120-120.	1.7	7
13	Comparative microbial antibiotic resistome between urban and deep forest environments. <i>Environmental Microbiology Reports</i> , 2021, 13, 503-508.	2.4	7
14	The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study. <i>Frontiers in Oncology</i> , 2021, 11, 646979.	2.8	23
15	Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 765-765.	1.7	3
16	Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. , 2021, 9, e001942.		22
17	Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 673248.	4.8	4
18	Association of chronic liver disease with the prognosis of COVID-19 patients. <i>Journal of Hepatology</i> , 2021, , .	3.7	1

#	ARTICLE	IF	CITATIONS
19	Letter to the Editor: Is Aspirin a Drug or Just a Marker for Biliary Cancer?. <i>Hepatology</i> , 2021, 74, 2924-2924.	7.3	0
20	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. <i>BMC Medicine</i> , 2021, 19, 154.	5.5	32
21	The Prognostic Value of Systemic Inflammation Response Index in Cholangiocarcinoma Patients. <i>Cancer Management and Research</i> , 2021, Volume 13, 6263-6277.	1.9	8
22	Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 434-442.	1.5	28
23	Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer. <i>Nature Communications</i> , 2021, 12, 4753.	12.8	12
24	Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1248.	7.1	0
25	Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. <i>Journal of Cancer</i> , 2021, 12, 1555-1562.	2.5	7
26	Mutational spectrum and precision oncology for biliary tract carcinoma. <i>Theranostics</i> , 2021, 11, 4585-4598.	10.0	39
27	LncRNA CYTOR affects the proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells by regulating the miR-125b-5p/KIAA1522 axis. <i>Aging</i> , 2021, 13, 2626-2639.	3.1	22
28	Identification of TMB, CD8 T cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit-toxicity ratio of anti-PD-1/PD-L1 therapy. <i>Clinical and Translational Medicine</i> , 2021, 11, e598.	4.0	0
29	Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. , 2021, 9, e003334.		101
30	<p>Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 315-330.	3.7	31
31	<p>Preoperative Immune Prognostic Index Can Predict the Clinical Outcomes of Patients with Gallbladder Cancer: Single-Center Experience</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 12137-12150.	1.9	2
32	Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review. <i>Annals of Translational Medicine</i> , 2020, 8, 1246-1246.	1.7	17
33	Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2020, 89, 107135.	3.8	17
34	Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 414-424.	1.5	93
35	Novel nomograms based on immune and stromal scores for predicting the disease-free and overall survival of patients with hepatocellular carcinoma undergoing radical surgery. <i>Journal of Surgical Oncology</i> , 2020, 122, 1569-1579.	1.7	2
36	Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 7646-7662.	2.8	42

#	ARTICLE	IF	CITATIONS
37	<p>Prognostic Nomogram That Predicts Overall Survival of Patients with Distal Cholangiocarcinoma After Pancreatoduodenectomy</p>. Cancer Management and Research, 2020, Volume 12, 10303-10310.	1.9	7
38	Construction of a new immune-related signature based on three lncRNAs as the factor for prognosis prediction of hepatocellular carcinoma. Clinical and Translational Medicine, 2020, 10, e101.	4.0	0
39	N6-methyladenosine associated prognostic model in hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 633-633.	1.7	27
40	<p>Prognostic Significance of the Preoperative Lymphocyte to Monocyte Ratio in Patients with Gallbladder Carcinoma</p>. Cancer Management and Research, 2020, Volume 12, 3271-3283.	1.9	5
41	The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review. Cell Proliferation, 2020, 53, e12791.	5.3	23
42	<p>Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center</p>. Cancer Management and Research, 2020, Volume 12, 411-417.	1.9	3
43	Diagnosis and treatment of a diaphragmatic pheochromocytoma: A case report. International Journal of Surgery Case Reports, 2020, 71, 78-81.	0.6	1
44	Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review. Cell Proliferation, 2020, 53, e12772.	5.3	80
45	CeRNA regulatory network-based analysis to study the roles of noncoding RNAs in the pathogenesis of intrahepatic cholangiocellular carcinoma. Aging, 2020, 12, 1047-1086.	3.1	27
46	Development of an immune-related prognostic index associated with hepatocellular carcinoma. Aging, 2020, 12, 5010-5030.	3.1	26
47	Genomics and translational precision oncology for 803 patients with biliary tract cancer.. Journal of Clinical Oncology, 2020, 38, 4589-4589.	1.6	3
48	Prognostic value and underlying mechanism of KIAA0101 in hepatocellular carcinoma: database mining and co-expression analysis. Aging, 2020, 12, 16420-16436.	3.1	4
49	Î³-glutamyl transferase-to-platelet ratio based nomogram predicting overall survival of gallbladder carcinoma. World Journal of Gastrointestinal Oncology, 2020, 12, 1014-1030.	2.0	4
50	Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma. Current Cancer Drug Targets, 2020, 20, 875-886.	1.6	2
51	Signature based on molecular subtypes of deoxyribonucleic acid methylation predicts overall survival in gastric cancer. World Journal of Gastroenterology, 2020, 26, 6414-6430.	3.3	3
52	T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. American Journal of Cancer Research, 2020, 10, 4585-4606.	1.4	8
53	CK20 and lymph node involvement predict adverse outcome of malignant intraductal papillary neoplasm of the bile duct. Histology and Histopathology, 2020, 35, 449-456.	0.7	2
54	Paraneoplastic leukemoid reaction in a patient with sarcomatoid hepatocellular carcinoma: A case report. World Journal of Clinical Cases, 2019, 7, 1330-1336.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Liver graft rejection following immune checkpoint inhibitors treatment: a review. <i>Medical Oncology</i> , 2019, 36, 94.	2.5	27
56	DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. <i>Theranostics</i> , 2019, 9, 7251-7267.	10.0	99
57	Alteration in gut microbiota caused by time-restricted feeding alleviate hepatic ischaemia reperfusion injury in mice. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1714-1722.	3.6	30
58	Time-restricted feeding causes irreversible metabolic disorders and gut microbiota shift in pediatric mice. <i>Pediatric Research</i> , 2019, 85, 518-526.	2.3	32
59	<p>Preoperative neutrophil"lymphocyte and platelet"lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5157-5162.	1.9	14
60	Alterations in DNA Damage Repair Genes in Primary Liver Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4701-4711.	7.0	74
61	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	17.0	58
62	The fusion landscape of hepatocellular carcinoma. <i>Molecular Oncology</i> , 2019, 13, 1214-1225.	4.6	11
63	Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression. <i>Journal of Cellular Physiology</i> , 2019, 234, 18837-18848.	4.1	103
64	The application of single-cell sequencing technology in the diagnosis and treatment of hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 790-790.	1.7	11
65	GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer. <i>Analytical Cellular Pathology</i> , 2019, 2019, 1-13.	1.4	19
66	Acute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: two case reports and a literature review. <i>Annals of Translational Medicine</i> , 2019, 7, 795-795.	1.7	5
67	The diagnostic and prognostic role of RhoA in hepatocellular carcinoma. <i>Aging</i> , 2019, 11, 5158-5172.	3.1	16
68	Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. <i>Annals of Translational Medicine</i> , 2019, 7, 467-467.	1.7	24
69	CMTTdb: the cancer molecular targeted therapy database. <i>Annals of Translational Medicine</i> , 2019, 7, 667-667.	1.7	4
70	Complete or partial split in associating liver partition and portal vein ligation for staged hepatectomy: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2019, 25, 6016-6024.	3.3	9
71	Laparoscopic hepatectomy for patients who received enterostomy. <i>Journal of Minimal Access Surgery</i> , 2019, 15, 325.	0.7	1
72	Hepatobiliary case report and literature review of hepatic reactive lymphoid hyperplasia with positive anti-smooth muscle antibody and anti-nuclear antibody tests. <i>Translational Cancer Research</i> , 2019, 8, 1001-1005.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. <i>Nature Communications</i> , 2018, 9, 894.	12.8	67
74	Prognostic significance of the fibrinogen-to-albumin ratio in gallbladder cancer patients. <i>World Journal of Gastroenterology</i> , 2018, 24, 3281-3292.	3.3	56
75	Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. <i>BMC Cancer</i> , 2018, 18, 766.	2.6	42
76	Multidisciplinary management of hepatobiliary tumors in the era of precision medicine. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 381-382.	1.3	1
77	Prognostic significance of combined preoperative fibrinogen and CA199 in gallbladder cancer patients. <i>World Journal of Gastroenterology</i> , 2018, 24, 1451-1463.	3.3	35
78	Prognostic impact of the red cell distribution width in esophageal cancer patients: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2018, 24, 2120-2129.	3.3	23
79	MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development. <i>Hepatology Research</i> , 2017, 47, 80-94.	3.4	3
80	Edmondson grade predicts survival of patients with primary clear cell carcinoma of liver after curative resection: A retrospective study with long-term follow-up. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e312-e320.	1.1	14
81	Continuous Pringle maneuver does not affect outcomes of patients with hepatocellular carcinoma after curative resection. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e321-e330.	1.1	15
82	Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue. <i>International Journal of Cancer</i> , 2017, 140, 1324-1330.	5.1	19
83	Mps1/TTK: a novel target and biomarker for cancer. <i>Journal of Drug Targeting</i> , 2017, 25, 112-118.	4.4	59
84	Tea consumption and the risk of biliary tract cancer: a systematic review and dose-response meta-analysis of observational studies. <i>Oncotarget</i> , 2017, 8, 39649-39657.	1.8	17
85	Reassessment of different criteria for diagnosing post-hepatectomy liver failure: a single-center study of 1683 hepatectomy. <i>Oncotarget</i> , 2017, 8, 89269-89277.	1.8	14
86	Liver segmentation from CT images using a sparse priori statistical shape model (SP-SSM). <i>PLoS ONE</i> , 2017, 12, e0185249.	2.5	15
87	Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 107295-107302.	1.8	25
88	A call for scientific integrity. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 11(4), 205-206.	1.5	0
89	Gallbladder papillary neoplasms share pathological features with intraductal papillary neoplasm of the bile duct. <i>Oncotarget</i> , 2017, 8, 31532-31539.	1.8	12
90	Identification of hub genes involved in the development of hepatocellular carcinoma by transcriptome sequencing. <i>Oncotarget</i> , 2017, 8, 60358-60367.	1.8	8

#	ARTICLE	IF	CITATIONS
91	Systematic review and meta-analysis: cholecystectomy and the risk of cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 59648-59657.	1.8	13
92	Management of intrahepatic recurrence after resection for hepatocellular carcinoma exceeding the barcelona clinic liver cancer criteria. <i>Oncotarget</i> , 2017, 8, 110406-110414.	1.8	7
93	Potential application of neogalactosylalbumin in positron emission tomography evaluation of liver function. <i>World Journal of Gastroenterology</i> , 2017, 23, 4278.	3.3	0
94	Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer. <i>World Journal of Gastroenterology</i> , 2017, 23, 5787.	3.3	1
95	Response of <i>BRCA1</i> -mutated gallbladder cancer to olaparib: A case report. <i>World Journal of Gastroenterology</i> , 2016, 22, 10254.	3.3	24
96	A new avenue for obtaining insight into the functional characteristics of long noncoding RNAs associated with estrogen receptor signaling. <i>Scientific Reports</i> , 2016, 6, 31716.	3.3	8
97	Coffee and cancer risk: A meta-analysis of prospective observational studies. <i>Scientific Reports</i> , 2016, 6, 33711.	3.3	66
98	Feature Learning Based Random Walk for Liver Segmentation. <i>PLoS ONE</i> , 2016, 11, e0164098.	2.5	16
99	Combination treatment including targeted therapy for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 71036-71051.	1.8	44
100	Combined hepatocellular cholangiocarcinoma: Controversies to be addressed. <i>World Journal of Gastroenterology</i> , 2016, 22, 4459.	3.3	42
101	Dr.VIS v2.0: an updated database of human disease-related viral integration sites in the era of high-throughput deep sequencing. <i>Nucleic Acids Research</i> , 2015, 43, D887-D892.	14.5	15
102	Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 43770-43778.	1.8	79
103	Magnesium isoglycyrrhizinate inhibits inflammatory response through STAT3 pathway to protect remnant liver function. <i>World Journal of Gastroenterology</i> , 2015, 21, 12370.	3.3	31
104	Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. <i>Journal of Hepatology</i> , 2014, 61, 840-849.	3.7	131
105	Large liver mass in a patient with latent colon cancer. <i>Hepatobiliary Surgery and Nutrition</i> , 2014, 3, 50-1.	1.5	0
106	Intraductal papillary neoplasm of the bile duct. <i>World Journal of Gastroenterology</i> , 2013, 19, 8595.	3.3	126
107	Peripheral primitive neuroectodermal tumors arising in the pancreas: the first case report in Asia and a review of the 14 total reported cases in the world. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 51-60.	1.5	11
108	Twenty-eight years of repeated relapse of gastrointestinal stromal tumor. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 232-3.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Multiple liver lesions with dormant submandibular gland nodule. Hepatobiliary Surgery and Nutrition, 2013, 2, 284-5.	1.5	0
110	Diagnosis and treatment of hepatic angiomyolipoma. Hepatobiliary Surgery and Nutrition, 2012, 1, 19-24.	1.5	10
111	Gallbladder carcinoma post gallbladder-preserving cholecystolithotomy: a case report. Hepatobiliary Surgery and Nutrition, 2012, 1, 61-3.	1.5	0
112	Hepatobiliary cystadenomas and cystadenocarcinomas: a report of 33 cases. Liver International, 2011, 31, 1337-1344.	3.9	53
113	Prediction and identification of tumor-specific noncoding RNAs from human UniGene. Medical Oncology, 2010, 27, 894-898.	2.5	7
114	Severe adult ileosigmoid intussusception prolapsing from the rectum: A case report. Cases Journal, 2008, 1, 198.	0.4	12